Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,558 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NSCLC, Non Small Cell Lung Cancer Clear all
Completed Phase 1 Interventional

Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

NCT02122861
View directory record Official record
Conditions
Melanoma - Currently Enrolling, Non-small Cell Lung Cancer - Enrollment Completed, Sarcoma - Enrollment Completed
Interventions
ID-LV305
Biological
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

NCT06449313
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage III
Interventions
Cemiplimab-Rwlc
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • St Louis, Missouri • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Pembrolizumab

NCT02818920
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Neal Ready MD PhD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Lebanon, New Hampshire • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Phase 2 Interventional

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Volrustomig, Carboplatin, Pemetrexed, Ramucirumab, Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer

NCT00850785
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
DRibble vaccine
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 1 Interventional Results available

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

NCT05374538
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
VIC-1911, sotorasib
Drug
Lead sponsor
Vitrac Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Sacramento, California • North Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 20, 2026, 5:28 AM EDT
Withdrawn Phase 2 Interventional

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

NCT02607423
View directory record Official record
Conditions
Stage IIIA Non-Small Cell Lung Cancer
Interventions
Cisplatin, Computed Tomography, Docetaxel, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Pemetrexed Disodium, Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)

NCT00618917
View directory record Official record
Conditions
Esophageal, Toxicity
Interventions
Manganese Superoxide Dismutase Plasmid Liposome, carboplatin, paclitaxel, Radiation Therapy
Genetic · Drug · Radiation
Lead sponsor
Joel Greenberger
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Phase 2 Interventional

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

NCT04268550
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Selpercatinib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
306
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Anaheim, California + 251 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

NCT05256290
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
Interventions
silevertinib (BDTX-1535) monotherapy
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Hatha Yoga in Lung Cancer Couples

NCT01952860
View directory record Official record
Conditions
Lung Cancer
Interventions
Hatha Yoga, Questionnaires
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

NCT01042288
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Carboplatin, Pemetrexed, Panitumumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
13
States / cities
Fort Myers, Florida • Orlando, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

NCT04524689
View directory record Official record
Conditions
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Interventions
SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 1 Interventional

A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

NCT00461110
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
BMS-663513
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting No phase listed Observational

Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data

NCT06934343
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
144,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 3 Interventional Results available

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

NCT00004859
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, thalidomide, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
235
States / cities
Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

NCT04789668
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Triple-Negative Breast Carcinoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

NCT00265317
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
erlotinib, sunitinib, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Antioch, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

NCT00452413
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Malignant Solid Tumor
Interventions
enzastaurin, erlotinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

NCT04340882
View directory record Official record
Conditions
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Docetaxel, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

NCT02869789
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab in combination with Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478
View directory record Official record
Conditions
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer
Interventions
HER3-DXd
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

NCT04476797
View directory record Official record
Conditions
SBRT, NSCLC, Non-metastatic
Interventions
GC4711 +SBRT, Placebo +SBRT
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Greeley, Colorado • Loveland, Colorado • Columbus, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer

NCT00545948
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
13
States / cities
West Palm Beach, Florida • Chicago, Illinois • Charlotte, North Carolina + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 20, 2026, 5:28 AM EDT